Roaring Waters Capital Surpasses 6.55% Voting Rights in Poolbeg Pharma, Prompting Regulatory Disclosure

Overview of Poolbeg Pharma's Market and Regulatory Status

Poolbeg Pharma Plc, an Irish pharmaceutical company listed under ISIN GB00BKPG7Z60, operates within the regulated life sciences sector and complies with the Financial Conduct Authority’s Disclosure Transparency Rules (DTR). The company’s ordinary shares carry equal voting rights, and any material changes in ownership must be promptly disclosed to uphold market transparency and investor confidence.

This regulatory framework ensures that significant shifts in Poolbeg Pharma’s shareholder base, such as Roaring Waters Capital’s recent acquisition, are publicly reported to maintain fair market practices and provide all investors with timely, material information.

Details of Roaring Waters Capital’s Voting Rights Acquisition

Roaring Waters Capital increased its voting rights in Poolbeg Pharma from 5.74% to 6.55%, holding 50 million shares directly without involvement of derivatives like options or convertible securities. This straightforward equity stake was acquired on 21 July 2026, the same day the voting rights threshold was crossed, necessitating immediate disclosure under DTR5 regulations.

The direct ownership structure confirms that Roaring Waters Capital holds these shares outright, with no intermediary entities or derivative instruments affecting its voting power.

Regulatory Notification and Threshold Compliance

Crossing the 6.55% threshold triggered Roaring Waters Capital’s obligation to notify both Poolbeg Pharma and the Financial Conduct Authority without delay, which was fulfilled on 21 July 2026. This disclosure complies with DTR5 requirements designed to protect market integrity by ensuring shareholders report when voting rights cross key levels such as 5%, 10%, and beyond.

The submitted TR-1 form included comprehensive details such as the number of voting rights, percentage ownership, and confirmation of the absence of derivative instruments, providing full transparency to regulators and market participants.

Voting Rights Structure and Shareholding Composition

Roaring Waters Capital’s entire 6.55% voting rights position is held directly via ordinary shares, with no indirect holdings or derivative financial instruments impacting its stake. The shares, identified by ISIN GB00BKPG7Z60, carry one vote each, establishing a fixed voting power unless further share transactions occur.

This clear ownership structure enables investors and regulators to accurately assess Roaring Waters Capital’s influence within Poolbeg Pharma’s governance framework.

Shareholder Background and Irish Registration

Registered in Dublin, Ireland, Roaring Waters Capital’s notification does not disclose further details about its ownership structure, investment strategy, or beneficial owners. The absence of additional information aligns with regulatory filing standards, which only require expanded disclosure if higher thresholds are crossed.

Investors seeking more insight into Roaring Waters Capital’s intentions or portfolio will need to monitor future announcements or regulatory filings.

Timing and Market Disclosure

The voting rights threshold was crossed and disclosed on 21 July 2026, ensuring timely notification to Poolbeg Pharma’s management and shareholders. This prompt reporting supports market fairness by preventing information asymmetry and enabling all stakeholders to access material ownership changes simultaneously.

The notification, filed in Dublin, Ireland, establishes a formal public record of Roaring Waters Capital’s shareholding increase in Poolbeg Pharma.

Comparison with Previous Shareholding

Previously holding 5.74% voting rights, Roaring Waters Capital’s increase to 6.55% marks a 0.81 percentage point rise. Although the exact number of shares acquired in this transaction is not disclosed, the upward movement indicates ongoing accumulation and confidence in Poolbeg Pharma.

Investors should continue to monitor whether Roaring Waters Capital pursues further share purchases or strategic involvement, especially as crossing higher thresholds would prompt additional disclosures.

Absence of Financial Instruments and Derivative Positions

The notification confirms Roaring Waters Capital holds no derivative financial instruments such as options, warrants, convertible securities, or swaps that confer voting rights. This absence simplifies the shareholder’s voting rights profile and enhances transparency regarding its actual influence.

By holding only ordinary shares, Roaring Waters Capital’s voting power is fixed at 6.55% unless further share acquisitions or disposals occur.

Investor Considerations and Outlook

Roaring Waters Capital’s 6.55% stake represents a significant ownership interest in Poolbeg Pharma, potentially impacting company governance and strategic decisions. While below thresholds triggering takeover codes or board representation requirements, investors should observe any future stake increases or public statements clarifying the shareholder’s intentions.

Given Poolbeg Pharma’s pharmaceutical sector context, changes in major ownership can influence perceptions of company risk, growth potential, and governance dynamics.

Compliance with Disclosure Transparency Rules

The notification adheres to the Financial Conduct Authority’s Disclosure Transparency Rules, incorporating European regulatory standards into UK frameworks. The completed TR-1 form, including all required data fields and ISIN references, ensures regulatory compliance and public accessibility of ownership changes.

Poolbeg Pharma, as a listed company, is obligated to promptly disclose such notifications to maintain market transparency and investor confidence.